Register
Lorlatinib approved for ALK+ metastatic lung cancer |
Journal Updates
eMediNexus Coverage from: 
Lorlatinib approved for ALK+ metastatic lung cancer
eMediNexus,  06 November 2018
remove_red_eye 670 Views
#Internal Medicine #Oncology #Pathology and Lab Medicine

0 Read Comments                

The US Food and Drug Administration (FDA) has approved lorlatinib (Lorbrena, Pfizer) for use in the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors test positive for anaplastic lymphoma kinase (ALK+).
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!